Skip to content
value.today

Eikon Therapeutics, Inc.

EIKN
$290 Mmarket cap on Oct 30, 2026
Compare
World rank
#14,928
Revenue
—
annual
Net income
—
Employees
384
As of December 31, 2025
SEC filing

Eikon Therapeutics, Inc. in brief

Eikon Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Millbrae, California, USA. Its market value was $290 M on 30 October 2026, which makes it the 14,928th largest listed company in the world and the 2,908th largest in the USA on this site. It employs about 384 people. Its shares trade under the symbol EIKN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Eikon Therapeutics, Inc.

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.

From the company's annual report filed with the US SEC: read the report

Eikon Therapeutics, Inc. timeline

2 events, 2021–2026
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2026
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 5 February 2026; shares registered for exchange trading on 28 January 2026.

Events of Eikon Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$161 M$323 M$484 M$646 M

World rank over time

▼ down 3,421 places since 2026
2026-08-01: #11546#11,54620262026-10-30: #14967#14,9672026

Rank in USA: #2,426 (Aug 2026) · #2,912 (Oct 2026)

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2025: revenue —, net income $-68M—Mar ’25Three months to Jun 2025: revenue —, net income $-105M—Jun ’25Three months to Sep 2025: revenue —, net income $-71M—Sep ’25Three months to Mar 2026: revenue —, net income $-83M—Mar ’26Three months to Jun 2026: revenue —, net income $-88M—Jun ’26Three months to Sep 2026: revenue —, net income $-86M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-86M.

SEC filings

Official filings of Eikon Therapeutics, Inc. with the US Securities and Exchange Commission.

Balance sheet

Total assets
$595 M
Total liabilities
$312 M
Total equity
$-879 M

As of December-2025

Top 98 institutional investors in Eikon Therapeutics, Inc.#

As of Sep 30, 2026
98 institutions held 31.7 M shares (about 58.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 39.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Eikon Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1FMR LLC5,520,152+526,246 (+10.54%)10.19%$44 MNov 10, 2026
2BlackRock, Inc.4,869,276+587,851 (+13.73%)8.99%$39 MNov 13, 2026
3Foresite Capital Management IV, LLC1,943,6820 (0.00%)3.59%$16 MNov 16, 2026
4Merck & Co., Inc.1,666,6660 (0.00%)3.08%$13 MNov 13, 2026
5T. Rowe Price Investment Management, Inc.1,637,441+42,167 (+2.64%)3.02%$13 MNov 16, 2026
6Foresite Capital Management V, LLC1,318,9830 (0.00%)2.43%$11 MNov 16, 2026
7Capital World Investors1,175,9440 (0.00%)2.17%$9 MNov 12, 2026
8Price T Rowe Associates Inc /MD/1,110,649+105,614 (+10.51%)2.05%$9 MNov 16, 2026
9Alliancebernstein L.P.1,052,041+410,153 (+63.90%)1.94%$8 MNov 16, 2026
10Vanguard Capital Management LLC1,015,513+92,806 (+10.06%)1.87%$8 MNov 13, 2026
11EcoR1 Capital, LLC855,634+123,028 (+16.79%)1.58%$7 MNov 16, 2026
12Geode Capital Management, LLC754,499+197,544 (+35.47%)1.39%$6 MNov 6, 2026
13Regents Of The University Of California635,131New1.17%$5 MOct 26, 2026
14State Street Corp608,838+254,745 (+71.94%)1.12%$5 MNov 12, 2026
15Baker Bros. Advisors LP555,5550 (0.00%)1.03%$4 MNov 16, 2026
16StepStone Group LP523,467+128,127 (+32.41%)0.97%$4 MNov 17, 2026
17Soros Capital Management LLC484,6720 (0.00%)0.89%$4 MNov 13, 2026
18Millennium Management LLC419,095+286,075 (+215.06%)0.77%$3 MNov 16, 2026
19Walleye Capital LLC391,273New0.72%$3 MNov 13, 2026
20Canada Pension Plan Investment Board379,0240 (0.00%)0.70%$3 MNov 16, 2026
21Citadel Advisors LLC354,016+340,993 (+2618.39%)0.65%$3 MNov 16, 2026
22Franklin Templeton Inc350,0000 (0.00%)0.65%$3 MNov 12, 2026
23Affinity Asset Advisors, LLC298,001+200,000 (+204.08%)0.55%$2 MNov 13, 2026
24UBS Group AG278,904+14,972 (+5.67%)0.51%$2 MNov 10, 2026
25Charles Schwab Investment Management Inc259,531+77,426 (+42.52%)0.48%$2 MNov 16, 2026
Show all 98: investors 26 to 98
Institutional investors 26 to 98 in Eikon Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Morgan Stanley247,112+235,080 (+1953.79%)0.46%$2 MNov 13, 2026
27Northern Trust Corp246,016+70,089 (+39.84%)0.45%$2 MNov 16, 2026
28Vanguard Portfolio Management LLC223,019+74,124 (+49.78%)0.41%$2 MNov 13, 2026
29Vanguard Fiduciary Trust Co202,239+53,829 (+36.27%)0.37%$2 MNov 13, 2026
30Two Sigma Investments, LP184,198New0.34%$1 MNov 16, 2026
31Woodline Partners LP162,254New0.30%$1 MNov 16, 2026
32Ensign Peak Advisors, Inc142,498-27,992 (-16.42%)0.26%$1 MNov 12, 2026
33Comprehensive Financial Management LLC140,856+24,580 (+21.14%)0.26%$1 MNov 16, 2026
34Bank Of America Corp /de/137,457+99,882 (+265.82%)0.25%$1 MNov 16, 2026
35BNP Paribas Financial Markets137,415+128,906 (+1514.94%)0.25%$1 MNov 12, 2026
36BNP PARIBAS ASSET MANAGEMENT Holding S.A.134,4980 (0.00%)0.25%$1 MNov 13, 2026
37XTX Topco Ltd133,167+105,712 (+385.04%)0.25%$1 MNov 16, 2026
38Goldman Sachs Group Inc127,887New0.24%$1 MNov 16, 2026
39Alps Advisors Inc71,255+16,307 (+29.68%)0.13%$1 MNov 3, 2026
40Bank of New York Mellon Corp65,871+18,083 (+37.84%)0.12%$1 MNov 5, 2026
41Los Angeles Capital Management LLC63,830New0.12%$1 MNov 12, 2026
42Aquatic Capital Management LLC62,883New0.12%$1 MNov 16, 2026
43Jpmorgan Chase & Co56,951+46,627 (+451.64%)0.11%$0 MNov 12, 2026
44AQR Capital Management LLC52,492New0.10%$0 MNov 16, 2026
45Invesco Ltd.51,158+258 (+0.51%)0.09%$0 MNov 12, 2026
46Trexquant Investment LP48,500New0.09%$0 MNov 16, 2026
47EntryPoint Capital, LLC47,943New0.09%$0 MNov 13, 2026
48Nuveen, LLC46,312+17,324 (+59.76%)0.09%$0 MNov 10, 2026
49D. E. Shaw & Co., Inc.39,240New0.07%$0 MNov 16, 2026
50TCG Crossover Management, LLC37,9020 (0.00%)0.07%$0 MNov 16, 2026
51DCF Advisers, LLC33,792New0.06%$0 MNov 4, 2026
52Quadrature Capital Ltd28,399New0.05%$0 MNov 13, 2026
53Rhumbline Advisers27,856+3,373 (+13.78%)0.05%$0 MNov 10, 2026
54Deutsche Bank AG\27,230+5,708 (+26.52%)0.05%$0 MNov 6, 2026
55Y-Intercept (Hong Kong) Ltd20,297New0.04%$0 MOct 16, 2026
56MetLife Investment Management, LLC19,235+5,480 (+39.84%)0.04%$0 MNov 16, 2026
57ProShare Advisors LLC15,757-13,928 (-46.92%)0.03%$0 MOct 29, 2026
58Entropy Technologies, LP15,500New0.03%$0 MNov 13, 2026
59MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.15,320+5,339 (+53.49%)0.03%$0 MNov 16, 2026
60Tudor Investment Corp Et Al15,0000 (0.00%)0.03%$0 MNov 16, 2026
61Prelude Capital Management, LLC13,066New0.02%$0 MNov 16, 2026
62Squarepoint Ops LLC13,026New0.02%$0 MNov 9, 2026
63Barclays PLC12,462+7,827 (+168.87%)0.02%$0 MNov 6, 2026
64Vanguard Global Advisers, LLC11,991+3,507 (+41.34%)0.02%$0 MNov 13, 2026
65Integrated Wealth Concepts LLC10,946+46 (+0.42%)0.02%$0 MNov 17, 2026
66Osaic Holdings, Inc.10,535+10,000 (+1869.16%)0.02%$0 MNov 12, 2026
67Jump Financial, LLC10,400-7,669 (-42.44%)0.02%$0 MNov 13, 2026
68Creative Planning10,177New0.02%$0 MNov 2, 2026
69Pavaki Capital Management LLC10,000New0.02%$0 MOct 26, 2026
70Police & Firemen's Retirement System of New Jersey8,974+2,554 (+39.78%)0.02%$0 MNov 9, 2026
71Wells Fargo & Company/mn8,640-10,708 (-55.34%)0.02%$0 MNov 16, 2026
72New York State Common Retirement Fund6,2000 (0.00%)0.01%$0 MNov 17, 2026
73Royal Bank Of Canada3,555+771 (+27.69%)0.01%$0 MNov 16, 2026
74Legal & General Group Plc2,967+849 (+40.08%)0.01%$0 MNov 16, 2026
75Ameritas Investment Partners, Inc.2,855+880 (+44.56%)0.01%$0 MNov 13, 2026
76Russell Investments Group, Ltd.1,837+97 (+5.57%)0.00%$0 MNov 6, 2026
77Citigroup Inc1,573-15,206 (-90.63%)0.00%$0 MNov 4, 2026
78Tower Research Capital LLC (TRC)1,308-2,327 (-64.02%)0.00%$0 MNov 16, 2026
79Arax Advisory Partners1,208New0.00%$0 MNov 12, 2026
80IFP Advisors, Inc969+51 (+5.56%)0.00%$0 MOct 16, 2026
81Sterling Capital Management LLC921+731 (+384.74%)0.00%$0 MOct 22, 2026
82Allworth Financial LP594+94 (+18.80%)0.00%$0 MNov 17, 2026
83State of Wyoming363-186 (-33.88%)0.00%$0 MOct 28, 2026
84California State Teachers Retirement System3000 (0.00%)0.00%$0 MNov 13, 2026
85Global Retirement Partners, LLC252New0.00%$0 MNov 10, 2026
86Farther Finance Advisors, LLC149New0.00%$0 MOct 8, 2026
87Aspect Partners, LLC140+14 (+11.11%)0.00%$0 MOct 20, 2026
88UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC130New0.00%$0 MNov 16, 2026
89GAMMA Investing LLC128New0.00%$0 MOct 8, 2026
90Fortitude Family Office, LLC1210 (0.00%)0.00%$0 MOct 14, 2026
91EverSource Wealth Advisors, LLC95New0.00%$0 MNov 4, 2026
92True Wealth Design, LLC45New0.00%$0 MOct 13, 2026
93Caitong International Asset Management Co., Ltd17+13 (+325.00%)0.00%$0 MOct 29, 2026
94Essential Partners LLC15New0.00%$0 MOct 14, 2026
95Clearstead Advisors, LLC10New0.00%$0 MNov 6, 2026
96Rothschild Investment LLC7New0.00%$0 MNov 10, 2026
97SJS Investment Consulting Inc.6New0.00%$0 MOct 26, 2026
98SBI Securities Co., Ltd.20 (0.00%)0.00%$0 MOct 22, 2026

Mutual funds holding Eikon Therapeutics, Inc.#

86 funds hold shares worth $124 M (about 18.8% of the company). Since their previous reports 59 added shares and 9 sold, buying $25 M net.
Mutual funds holding Eikon Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity ContrafundFidelity Management & Research Company LLC1.28 M$17 M2.4%<0.01%no changeJun 30, 2026
🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc1.14 M$15 M2.1%0.02%no changeJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc.926,046$12 M1.7%0.11%+29%Jun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC974,333$11 M1.8%0.20%+219%May 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.660,117$9 M1.2%<0.01%−7.3%Jun 30, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC722,389$8 M1.3%0.13%no changeMay 29, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors510,661$7 M0.94%<0.01%newJun 30, 2026
🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC602,300$7 M1.1%<0.01%+38%May 31, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.349,098$5 M0.64%0.04%no changeJun 30, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.331,011$4 M0.61%0.03%−0.0%Jun 30, 2026
🇺🇸 Fidelity Contrafund K6Fidelity Management & Research Company LLC265,469$3 M0.49%<0.01%−1.3%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.235,174$3 M0.43%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC237,756$2 M0.44%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors140,757$2 M0.26%0.01%newJun 30, 2026
🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC169,228$2 M0.31%<0.01%+37%May 31, 2026
🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC154,400$2 M0.28%<0.01%+38%May 31, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC121,628$2 M0.22%0.15%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC140,013$1 M0.26%0.05%+0.8%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC109,803$1 M0.20%<0.01%newMay 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.127,376$1 M0.24%0.10%no changeJul 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.99,752$1 M0.18%<0.01%newMay 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors72,988$1 M0.13%0.06%newJun 30, 2026
🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P.70,430$1 M0.13%0.11%newJun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors63,966$1 M0.12%<0.01%newJun 30, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC63,218$1 M0.12%0.14%no changeJun 30, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC43,100$1 M0.08%0.15%no changeJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC40,689$1 M0.08%<0.01%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.52,895$0 M0.10%<0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC44,280$0 M0.08%<0.01%newMay 31, 2026
🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P.35,180$0 M0.06%0.01%−93%Jun 30, 2026
🇺🇸 SMALLCAP World FundCapital Research and Management Company32,307$0 M0.06%0.02%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC32,257$0 M0.06%<0.01%newMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC30,772$0 M0.06%<0.01%newMay 31, 2026
🇺🇸 AVIP AB Small Cap PortfolioCONSTELLATION INVESTMENTS INC23,796$0 M0.04%0.10%−2.3%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC22,893$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.20,976$0 M0.04%0.04%no changeJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC28,988$0 M0.05%<0.01%newJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation16,200$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC14,003$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.15,556$0 M0.03%<0.01%newMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.11,999$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.11,243$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.14,000$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.11,872$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC9,499$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.9,490$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC7,797$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC7,439$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC10,357$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC7,211$0 M0.01%0.04%no changeJun 30, 2026
🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC6,500$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC6,108$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.5,800$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC5,071$0 M<0.01%0.04%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC4,880$0 M<0.01%0.03%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS4,748$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC4,733$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.3,408$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.3,321$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC4,212$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC2,902$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,680$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC2,680$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC2,606$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,216$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.2,923$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,975$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC2,549$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,740$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,611$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC1,337$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,893$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 AVIP Fidelity Institutional AM Equity Growth PortfolioCONSTELLATION INVESTMENTS INC1,300$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,042$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC1,031$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.1,156$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC908$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,276$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Guardian Large Cap Fundamental Growth VIP FundPark Avenue Institutional Advisers LLC900$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC755$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.549$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC428$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC510$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.367$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC245$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.218$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 86 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Eikon Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$47.2 M
10 purchases, 6 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$47.2 M
open market only
Insiders on file
7
since
$46.1 M$0Feb 2026: bought $46.1 M (9 trades), sold $0 (0 trades)Feb 26Sep 2026: bought $1.0 M (1 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Eikon Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Tim Kutzkey10% ownerBuyindirect+89,200$11.56$1.0 M89,200Form 4
filed Roger M. PerlmutterSee remarks, DirectorConversionindirect+284,857——284,857Form 4
filed Column Group Opportunity III, LP10% ownerConversionindirect+1.30 M——1.36 MForm 4
filed Column Group Opportunity III, LP10% ownerConversionindirect+1.40 M——2.76 MForm 4
filed Column Group Opportunity III, LP10% ownerConversionindirect+110,928——2.87 MForm 4
filed Column Group Opportunity III, LP10% ownerConversionindirect+44,249——47,601Form 4
filed Column Group Opportunity III, LP10% ownerConversionindirect+47,898——95,499Form 4
filed Column Group Opportunity III, LP10% ownerConversionindirect+3,785——99,284Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Eikon Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.5 M
10.47 days to cover
Shares sold short, last 18 reportsAll stocks →

IPO: priced at $18.00, raising $381.2M · IPO calendar

Fails to deliver

  • : 18 shares at $5.35
  • : 8,909 shares at $5.55
  • : 175 shares at $5.54
  • : 1,428 shares at $8.18
  • : 222 shares at $7.33

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Eikon Therapeutics, Inc. scorecard#

Passes 1 of the 2 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 1
    • –P/E below its peers' medianNo P/E on file.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • –Earnings yield above the 10-year Treasury yieldNo P/E on file.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • ✓Short-term assets cover short-term liabilities6.3×Current ratio 6.34 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Events at Eikon Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Bylaws or fiscal year changed 1 · Results announced 4

Eikon Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Eikon Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2025$351 MNo. 4$250 million to $1 billion27equity, optionsSEC
May 2023$141 MNo. 3$50 to $250 million21equitySEC
Dec 2021$518 MNo. 2$250 million to $1 billion43equitySEC
May 2021$103 MNo. 1$50 to $250 million12equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Eikon Therapeutics, Inc.#

19 labor condition applications certified in fiscal 2026 for 19 positions, at a median wage of $144 K a year.

Certified, FY2026
19
#612 among companies on value.today
Worker positions
19
Median wage offered
$144 K
a year, full-time
Applications filed
19
Eikon Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Biologist (Sr. Research Associate)Molecular and Cellular Biologists2$113 K
Assoc. Dir., Clinical Study ManagementClinical Research Coordinators1$184 K
Associate Director, Clinical Data Analytics and ReportingData Scientists1$207 K
Clinical Trial Mgmt AssocClinical Research Coordinators1$107 K
Engineer, SoftwareSoftware Developers1$130 K
Lab Data ManagerClinical Data Managers1$109 K
Lead Veeva Vault AdminComputer Systems Analysts1$149 K
Manager, Clin Trial Master File AdminClinical Data Managers1$140 K
Manager, Regulatory Submission PublisherRegulatory Affairs Managers1$105 K
Manager, Software EngineeringComputer and Information Systems Managers1$183 K

Where: Jersey City, NJ 9 · Millbrae, CA 7 · Los Angeles, CA 1 · Portland, OR 1 · Hayward, CA 1

Eikon Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY20261919$144 K19
FY20251313$153 K13
FY20241919$138 K19
FY202388$146 K8
FY202233$156 K3
FY202122$178 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Eikon Therapeutics, Inc.

Layoffs at Eikon Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
55
2025–2025
Latest
55 people
2025-05-21
Eikon Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025····55·······55
Eikon Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
effective 55 peopleLayoffWARN noticeMillbrae, CaliforniaNotice list

Source: State WARN notices and SEC 8-K item 2.05

Discuss Eikon Therapeutics, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    Eikon Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $86 million.

  • Mutual funds: 86 funds hold $124 millionautomatic update · Jul 31, 2026

    86 mutual funds in 1 country hold shares of Eikon Therapeutics, Inc. worth $124 million, about 18.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 59 funds added shares and 9 sold; on balance they bought $25 million. Share splits are not counted as trading.

How Eikon Therapeutics, Inc. compares in Biotechnology

  • Market cap$290 M · higher than 50% of 726

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Eikon Therapeutics, Inc.🇺🇸$290 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Eikon Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Eikon Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Eikon Therapeutics, Inc.? Suggest a correction